Georgia Bio Names Milton High School Senior as 2021 Georgia BioGENEius Winner

Priya Soneji Advances to International Competition Against Top Students

ATLANTA–( BUSINESS WIRE )–Georgia Bio and the Georgia BioEd Institute today named  Priya Soneji , a senior at Milton High School in Milton, GA, as the winner of the 2021 Georgia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. As Georgia’s BioGENEius finalist, Priya will attend the 2021 International BioGENEius competition, which will be held virtually and featured during the BIO Digital Convention.

“In the biotech industry, young people are the closest thing we have to a crystal ball. The BioGENEius Challenge showcases scientific innovations that are only possible when young minds are given the freedom and resources to convert their ideas into action” Tweet this

Priya will compete against high school students from the U.S., Canada and Germany in the International BioGENEius Challenge. The student projects will represent a range of biotechnology topics such as healthcare, agriculture, and the environment.

Priya was selected as our winner because of the tracking microscope she developed that automatically focuses on a microorganism as it travels through three-dimensional space. Scientists typically observe microorganisms under a microscope by moving the slide or petri dish manually. Priya improved on this method by creating a mechanized device that uses AI to record video and plot the location of an organism as it travels. By enabling scientists to observe microscopic organisms for longer periods of time and more easily identify fast-moving specimens, this device has the potential to facilitate parasite diagnosis and advance the discovery of previously unknown microorganism behaviors.

“In the biotech industry, young people are the closest thing we have to a crystal ball. The BioGENEius Challenge showcases scientific innovations that are only possible when young minds are given the freedom and resources to convert their ideas into action,” said Georgia Bio President and CEO Maria Thacker. “Georgia Bio is thrilled to have Priya represent our state on the international stage at the upcoming BIO Digital Convention, and we are proud to support this Georgia scholar in her future endeavors.”

Georgia Bio also congratulates the Georgia BioGENEius runner-up,  Asmi Kumar,  who is also a student at Milton High School in Milton, GA. Asmi’s project focused on treating Cortical Visual Impairment (CVI) with a low-cost, computer app-based therapy, called FollowMe. CVI occurs when neurological damage in a child’s brain causes a disconnect between the optic nerve and the visual cortex. Typically, the connection is restored through coordination therapies, where parents or therapists move an object around in front of a child so that the child may track it. This method is often expensive, time-consuming, and results in inconsistent feedback on what the child’s eyes are seeing. FollowMe uses AI and a standard webcam to track the patient’s gaze as they follow targets generated in the web-based app, which eliminates the need for expensive therapy visits. Asmi plans to continue the development of FollowMe and hopes to introduce this therapy to doctors around the world.

Judging the 2021 Georgia BioGENEius Challenge were Jamie L. Graham, Boehringer Ingelheim; Ralph L. Cordell, CDC; Ian Biggs, UGA; and Alex Harvey, ViaMune, Inc.

National and International winners will be announced after the competition. See the  International BioGENEius website  for more information on the revised 2021 schedule. Winners will receive cash scholarships.

Follow the BioGENEius Challenge:  Throughout the challenge, @BiotechInstitut will be tweeting interviews, photos, and engaging with the biotechnology community by using the hashtag #BioGENEius.

About the Biotechnology Institute

The Biotechnology Institute is an independent, national nonprofit organization dedicated to education about the present and future impact of biotechnology. Its mission is to engage, excite and educate the public, particularly students and teachers, about biotechnology and its immense potential for solving human health, food and environmental problems. For more information, visit  www.biotechinstitute.org.

About the Georgia BioEd Institute

The Georgia BioEd Institute, a division of the 501(c)(3) nonprofit the Center for Global Health Innovation, works to strengthen Georgia’s life sciences workforce pipeline through classroom-to-career initiatives that align with industry needs. BioEd works closely with its sister organization Georgia Bio, which serves the state’s life science industry. For more information about BioEd, visit them online at  www.georgiabioed.org , or on Facebook (@GeorgiaBioEd), Twitter (@georgiabioed), or LinkedIn (@georgia-bioed).

Biotech Leaders Launch National Alliance to Define the Future of American Innovation

May 5, 2026
New coalition forms to develop a national innovation roadmap to strengthen and extend  America’s global leadership in biotechnology

UGA & Manus Among Awardees in $214M BioMADE Investment

April 30, 2026
BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities

Nutrivert announces first close on $6 million Series A-2 funding round

April 17, 2026
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.
MORE POSTS